International Assets Investment Management LLC Makes New $1.03 Million Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

International Assets Investment Management LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 27,868 shares of the biopharmaceutical company’s stock, valued at approximately $1,030,000.

Other institutional investors also recently modified their holdings of the company. EP Wealth Advisors LLC acquired a new position in Halozyme Therapeutics in the third quarter valued at $211,000. Pathstone Family Office LLC acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at about $219,000. Tocqueville Asset Management L.P. bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $225,000. Gallacher Capital Management LLC acquired a new stake in Halozyme Therapeutics during the third quarter worth approximately $235,000. Finally, Dark Forest Capital Management LP bought a new stake in Halozyme Therapeutics in the third quarter worth approximately $236,000. 97.79% of the stock is owned by institutional investors.

Insider Activity

In related news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $39.55, for a total transaction of $395,500.00. Following the transaction, the senior vice president now directly owns 156,558 shares in the company, valued at $6,191,868.90. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 30,000 shares of company stock worth $1,196,800 over the last quarter. Insiders own 2.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on HALO shares. JMP Securities restated a “market outperform” rating and set a $72.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, February 21st. StockNews.com raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 23rd. TheStreet lowered shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, January 22nd. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, April 17th. Finally, Morgan Stanley dropped their price target on Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 26th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $53.29.

Halozyme Therapeutics Price Performance

HALO stock opened at $38.71 on Tuesday. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64. The business has a 50-day simple moving average of $39.56 and a two-hundred day simple moving average of $37.77. The company has a market capitalization of $4.92 billion, a P/E ratio of 18.35, a price-to-earnings-growth ratio of 0.45 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 52-week low of $29.85 and a 52-week high of $45.00.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). The company had revenue of $230.04 million for the quarter, compared to analysts’ expectations of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. Research analysts expect that Halozyme Therapeutics, Inc. will post 3.45 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.